Morning Call, May 23
Health Care: Drugs
CytRx Corporation (CYTR: NASDAQ)
$2.34 0.03 | 1.30%
05/23/13 - 04:00 PM ET
84.79K / 151.20K
Vol / Avg. Vol:2.30 / 2.31
Open / Prev. Close:2.25 - 2.39
Today's Range:1.59 - 5.50
52 Wk Range:29.41%
Performance YTD:TheStreet Rating:
Portfolios with CYTR
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- Uservlady 1
- Contributor5 Stocks Under-$10 Setting ...
- UserHope For The Best
- Userrick epple
- ContributorBarron's Research Reports 1...
Latest CYTR Headlines from TheStreet
- 5 Stocks Poised for Breakouts 04.19.13 | 02:04 pm
- 8 Stocks Under $10 Moving Higher 02.28.13 | 11:02 pm
- 5 Stocks With Big Insider Buying 10.24.12 | 12:10 pm
- Insiders Trading DVA CYTR JBHT HNSN 10.19.12 | 09:10 am
- 5 Stocks With Big Insider Buying 07.03.12 | 12:07 pm
- 5 Stocks Under $10 With Big Upside Potential 11.18.11 | 06:11 am
- SeaChange, Tenet: Early Volume Plays 12.03.09 | 08:12 am
- CytRx: FDA Lifts 2-year Hold On Arimoclomol Tests 12.02.09 | 09:12 am
- Correction: CytRx FDA Letter 09.09.09 | 04:09 pm
- CytRx Expects To File FDA Response In 4Q 09.08.09 | 10:09 am
Press Releases for CYTR
- CytRx To Present At The 25th Annual ROTH Conference - Business Wire 03.12.13 | 08:03 am
- CytRx Reports 2012 Financial Results - Business Wire 03.11.13 | 08:03 am
- CytRx To Present At The Cowen & Company 33rd Annual Health Care Conference - Business Wire 03.01.13 | 08:03 am
- CytRx Reaches Patient Enrollment Target In Global Phase 2b Clinical Trial With Tamibarotene As First-Line Treatment For Non-Small-Cell Lung Cancer - Business Wire 02.28.13 | 08:02 am
- CytRx To Present At The 2013 Leerink Swann Global Healthcare Conference - Business Wire 02.06.13 | 08:02 am
- CytRx To Present At The BIO CEO & Investor Conference - Business Wire 02.04.13 | 08:02 am
- CytRx Receives Recommendation From Data Safety Monitoring Committee To Complete Global Phase 2b Clinical Trial With Tamibarotene As First-Line Treatment For Non-Small-Cell Lung Cancer - Business Wire 01.31.13 | 08:01 am
- CytRx Announces Positive Results From Animal Trial With Combination Aldoxorubicin And Doxorubicin Therapy - Business Wire 01.28.13 | 08:01 am
- The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Directors Of CytRx Corporation In Connection With Executive Compensation - PR Newswire 01.23.13 | 02:01 pm
- CytRx Promotes Dr. Daniel Levitt To Executive Vice President - Business Wire 01.03.13 | 08:01 am
Partner Headlines for CYTR
- Zacks #1 Rank Additions for Thursday - Tale of the Tape - Zacks 11.29.12 | 09:11 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 11.20.12 | 09:11 am
- Biotechs to Watch at the 2012 San Francisco Healthcare Confrences - Analyst Blog - Zacks 01.09.12 | 07:01 am
- Why CytRx Corporation Is Still A Big Biotech 'If' Play - Seeking Alpha 12.14.11 | 09:12 am
- CytRx Is Poised For Growth - Analyst Blog - Zacks 08.13.11 | 12:08 am
- CytRx Reports 2Q 2011 Results - Analyst Blog - Zacks 08.12.11 | 06:08 pm
- As the Market Dips, It's Time to Look for Biotech Sector Deals - Seeking Alpha 06.12.11 | 09:06 am
- CytRx Completes Sale of Molecular Chaperone Assets - Analyst Blog - Zacks 05.17.11 | 09:05 am
- Company News for April 29, 2011 - Corporate Summary - Zacks 04.29.11 | 10:04 am
- Stocks Mixed at Session's Half on Slowing Q1 Economy; Crude Futures Advance - NASDAQ 04.28.11 | 04:04 pm
